A similar observation was made in CD38+ CLL patients (median, IQR; 0.16, 0.21–0.06) versus CD38− ones (median, IQR; 0.03, 0.058–0.02) (p < 0.0001) (Figure 3(b)). This evidence concerns the gene CD38 and B-cell chronic lymphocytic leukemia.